Is CGM next?
There is no question that CGM is transformational technology. Study after study has shown CGM improves outcomes for both Type 1 and Type 2 patients. But the benefits of CGM expand beyond patients with diabetes to regular folk using the technology to improve their health. As we have said many times the usage we see today is just the tip of the iceberg. Under the waterline is far greater population. Here...
Finger-pointing or The Texas Two Step
Anyone who participates on social media and follows diabetes related stories or posts has likely seen the proliferation of ads for what looks to be non-invasive glucose monitors that shockingly look like an Apple Watch. None of these devices are FDA approved nor has any undergone the rigors of the clinical process. These knockoffs as we call them are jumping on the CGM bandwagon. As we have noted in the past...
Looking ahead
Before we take a look at the results released by Novo Nordisk and Lilly a reminder that we did publish on the Insulet results, yet it seems some subscribers did not receive the post. We did republish the post later in the day and it can be viewed by logging into the site. It’s possible some subscribers received the post twice while others did not get it once. Obviously, we...
A battle for second
Just as a quick FYI some of you might be getting this twice With the run for the roses this weekend one wonders if we’ll ever see the likes of Secretariat ever again. Widely acknowledged as the greatest racehorse of all time Secretariat didn’t just win the Triple Crown but did so in convincing fashion winning the Belmont by an amazing 31 lengths. Basically, it was Secretariat way out front and...
It’s now a battle for second.
With the run for the roses this weekend one wonders if we’ll ever see the likes of Secretariat ever again. Widely acknowledged as the greatest racehorse of all time Secretariat didn’t just win the Triple Crown but did so in convincing fashion winning the Belmont by an amazing 31 lengths. Basically, it was Secretariat way out front and a battle for second place. This is exactly what’s happening right this...
Hidden in plain sight.
As we anticipated and predicted things would get worse before that get better at Tandem. Looking at their results released yesterday it’s evident the company continues to struggle. The Omnipod 5 still remains the hottest thing going and now Tandem faces a new threat with the recently approved 780 which is getting some early positive reviews. Although we have no advanced knowledge of what Insulet will say later today we...
Been there done that.
Back in the day before MiniMed was acquired by Medtronic an executive said running an insulin pump company is like running an airline, you never shut down. Insulin pumps have become much smarter since then, there are new forms of information readily available to patients, yet this is a medical device and as much patients don’t like it medical devices fail and/or malfunction. Perhaps the biggest strategic blunder made by Medtronic...